Fischer J R, Schindel M, Bülzebruck H, Lahm H, Krammer P H, Drings P
Thoraxklinik-Heidelberg GmbH, Department of Medical Oncology, Amalienstrasse 5, 69126 Heidelberg-Rohrbach, Germany.
J Cancer Res Clin Oncol. 2000 Dec;126(12):730-3. doi: 10.1007/pl00008479.
We have previously reported significant impairment of IL-2 secretion in patients with small cell lung cancer (SCLC) at the time of diagnosis. Impairment of IL-2 secretion correlated with reduced survival in SCLC. This new prognostic factor was independent of other factors of prognostic relevance in SCLC. The prognostic value of IL-2 secretion was comparable to the most predominant prognostic factors for survival in SCLC identified so far. We now report long-term survival data from these patients.
The significance of correlations between single parameters in the test groups was calculated by using linear regression analysis, the Wilcoxon rank sum test, and Fisher's exact test. Using the Kaplan-Meier method, the log-rank test and the Cox regression model, we analyzed the relation of IL-2 secretion in whole blood cell cultures from 52 patients with SCLC at the time of diagnosis to established prognostic factors relevant for survival in SCLC.
IL-2 secretion correlates with survival in SCLC. In addition, survival analysis according to tumor response and level of IL-2 secretion at the time of diagnosis demonstrates that long-term survival can only be observed after complete response to chemotherapy and high initial IL-2 secretion.
IL-2 secretion at the time of diagnosis represents an independent prognostic factor for survival in SCLC. Moreover, long-term survival is only observed in patients with complete response upon chemotherapy that showed high IL-2 secretion at diagnosis. Therefore, IL-2 secretion may partially define long-term survival in this disease. These results have to be confirmed in a larger patient population.
我们之前报道过，小细胞肺癌（SCLC）患者在诊断时白细胞介素-2（IL-2）分泌存在显著受损。IL-2分泌受损与SCLC患者生存率降低相关。这一新型预后因素独立于SCLC其他具有预后相关性的因素。IL-2分泌的预后价值与目前已确定的SCLC生存最主要预后因素相当。我们现在报告这些患者的长期生存数据。
通过线性回归分析、Wilcoxon秩和检验及Fisher精确检验计算测试组中单个参数之间相关性的显著性。使用Kaplan-Meier法、对数秩检验和Cox回归模型，我们分析了52例SCLC患者诊断时全血细胞培养中IL-2分泌与SCLC生存相关既定预后因素之间的关系。
IL-2分泌与SCLC患者的生存相关。此外，根据肿瘤反应和诊断时IL-2分泌水平进行的生存分析表明，只有在化疗完全缓解且初始IL-2分泌水平高时才能观察到长期生存。
诊断时的IL-2分泌是SCLC患者生存的独立预后因素。此外，只有在化疗完全缓解且诊断时IL-2分泌水平高的患者中才能观察到长期生存。因此，IL-2分泌可能部分决定了该疾病的长期生存。这些结果必须在更大的患者群体中得到证实。
